Seven new agents including BRAF inhibitors (vemurafenib and dabrafenib), MEK inhibitor (trametinib and cobimetinib), anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor ipilimumab, programmed death 1 (PD-1) inhibitors (nivolumab and pembrolizumab) and talimogene laherparepvec have demonstrated improved survival and are approved singly and in combination for the management of advanced melanoma [5–14]. Here, BRAF is linked to melanoma.